Table 2

Results of genetic burden analysis using TASER methodology, with 128 cases and 248 controls

GeneChr (position)LM_sM_stM_pNew.SB_pNew.STB_pAdjusted
p value
LOC28368515 (23684612–23685207)217772.34E-062.34E-067.41E-06
OR4C4511 (48366903–48373999)149997.72E-067.72E-062.18E-05
KCNJ1217 (21279699–21323179)178363635.59.63E-069.63E-062.67E-05
PSMD23 (184017022–184026675)746665.65E-055.65E-051.32E-04
BX64848920 (25825303–25834657)181010106.34E-056.34E-051.47E-04
ANKFY117 (4066665–4167025)718886.79E-058.15E-051.84E-04
FRG1B20 (29612306–29631629)501414149.94E-059.94E-052.21E-04
LRRTM42 (76974850–77749502)475551.06E-041.06E-042.34E-04
MLLT10P120 (29637584–29638138)212020201.41E-041.41E-043.03E-04
ADCY17 (45613739–45703971)301111.81E-041.81E-043.80E-04
  • Adjusted p value, p value after applying genomic control correction (inflation factor λ=1.11) to the New.STP_p χ2 test statistic; L, number of variant sites that are considered ‘rare’ (alternate allele read count frequency AACF <0.05); M_p, estimated number of SNVs in the dataset; M_s, number of variant sites screened in; M_st, number of variant sites screened in and passing threshold AACF >1/(2n), where n=128+248 (the cohort size); New.SB_p, p value of the ‘New-SB’ test (based on M_s); New.STP_p, p value of the ‘New-STB’ test (based on M_st).